NDNicholas Allen Deebel

Nicholas Allen Deebel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicholas Allen Deebel has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Associations between erectile dysfunction, low testosterone, and cardiometabolic risk: an age stratified, propensity-matched cohort study

    by Gal Saffati, Carlos Riveros, Obinna Obuekwe, Skyler Howell, Nicholas Deebel, Taylor Kohn, Akhil Muthigi

    Erectile dysfunction (ED) and low testosterone (low T) may serve as early markers of cardiometabolic disease. We conducted a retrospective cohort study using TriNetX, including 3 494 600 U.S. men aged 18-70 years with ED, low T, or both conditions, to evaluate associations with incident diabetes, metabolic syndrome (MetS), cardiovascular disease (CVD), hypertension, and obesity identified using ICD codes. Subgroup analysis assessed the impact of testosterone replacement therapy (TRT) on cardiometabolic outcomes in men with low T. In men aged 41-50 years, low T was associated with increased risk of diabetes (HR 1.89, p < 0.001) and MetS (HR 1.44, p < 0.001). TRT use was associated with decreased risk of diabetes (HR 0.88, p = 0.023). ED was associated with increased risk of CVD across all age groups, including men aged 41-50 years (HR 2.54, p < 0.001). Young men aged 18-30 with both low T and ED exhibited greater risk of obesity (HR 1.49, p < 0.001) and MetS (HR 2.61, p < 0.001) compared with ED alone. These findings suggest that ED and low T represent early clinical indicators of cardiometabolic disease and highlight the importance of early risk stratification in affected men.


  • Vasectomy reversal: lessons learned to optimize clinical outcomes

    by Nicholas A. Deebel, Evan Panken, Hannah Moreland, Madeline Snipes, Stephen Tranchina, Kevin Parham, Farah Rahman, Rafael Carrion, Kimberly Waggener, Robert Brannigan

    Vasectomy reversal (VR) has remained the longstanding gold standard for men seeking paternity following a history of vasectomy. Ever since its initial description, numerous innovations have occurred in the field of reproductive urology to optimize perioperative outcomes. Additional considerations such as preoperative patient and patient's partner evaluation, medical optimization, and perioperative surveillance protocols are now a paramount component of caring for patients with obstructive azoospermia undergoing vasectomy reversal. Finally, numerous surgical innovations have been described which may lead to increased duration of patency in the postoperative setting. This review aims to provide a comprehensive update on the management of obstructive azoospermia secondary to vasectomy and all salient considerations including preoperative evaluation, intraoperative decision making, surgical technique, and postoperative surveillance.


  • Utilization of artificial intelligence in Men’s Health: Opportunities for innovation and quality improvement

    by Haley Clark, Nikit Venishetty, Skyler Howell, Nicholas A. Deebel, Akhil Muthigi

    Artificial intelligence (AI) is reshaping the landscape of men’s health by enhancing diagnostic accuracy, personalizing treatment strategies, and improving clinical efficiency. This narrative review explores the applications and ethical considerations of AI technologies, including machine learning, deep learning, and natural language processing, in key areas of men’s health such as fertility, erectile dysfunction, Peyronie’s disease, testosterone deficiency, and premature ejaculation. In reproductive medicine AI improves sperm morphology assessment, embryo selection, and prediction of seminal quality, offering more objective and accurate alternatives to traditional methods. For erectile dysfunction, AI supports diagnosis through advanced imaging, wearable sensors, and predictive modeling, while also contributing to drug discovery. In the context of Peyronie’s disease, AI enhances curvature assessment and three-dimensional modeling, improving diagnostic precision and surgical planning. AI also holds promise in improving the evaluation of testosterone deficiency by optimizing symptom questionnaires. Furthermore, AI-powered chatbots are emerging as accessible tools for patient education across various men’s health topics, including pre-consultation support for conditions such as premature ejaculation and vasectomy counseling. Despite AI’s advancements in men’s health, challenges remain in ensuring ethical implementation, protecting data privacy, patient autonomy, and promoting algorithm transparency. This review highlights the transformative potential of AI in the future of men’s health while emphasizing the importance of responsible integration guided by clinical validation, regulatory oversight, and adherence to ethical principles.


  • Progression From Andrology Fellowship to the Workforce: Lessons Learned and Tactical Points for Consideration

    by Nicholas A. Deebel, Brittany Berk, Raevti Bole, Juan Andino, Jeffrey Morrison, Akhil Muthigi

  • Open Access

    In Vitro Generation of Haploid Germ Cells from Human XY and XXY Immature Testes in a 3D Organoid System

    by Guillermo Galdon, Nima Pourhabibi Zarandi, Nicholas A. Deebel, Sue Zhang, Olivia Cornett, Dmitry Lyalin, Mark J. Pettenati, YanHe Lue, Christina Wang, Ronald Swerdloff, et al.

    Increasing survival rates of children following cancer treatment have resulted in a significant population of adult survivors with the common side effect of infertility. Additionally, the availability of genetic testing has identified Klinefelter syndrome (classic 47,XXY) as the cause of future male infertility for a significant number of prepubertal patients. This study explores new spermatogonia stem cell (SSC)-based fertility therapies to meet the needs of these patients. Testicular cells were isolated from cryopreserved human testes tissue stored from XY and XXY prepubertal patients and propagated in a two-dimensional culture. Cells were then incorporated into a 3D human testicular organoid (HTO) system. During a 3-week culture period, HTOs maintained their structure, viability, and metabolic activity. Cell-specific PCR and flow cytometry markers identified undifferentiated spermatogonia, Sertoli, Leydig, and peritubular cells within the HTOs. Testosterone was produced by the HTOs both with and without hCG stimulation. Upregulation of postmeiotic germ cell markers was detected after 23 days in culture. Fluorescence in situ hybridization (FISH) of chromosomes X, Y, and 18 identified haploid cells in the in vitro differentiated HTOs. Thus, 3D HTOs were successfully generated from isolated immature human testicular cells from both euploid (XY) and Klinefelter (XXY) patients, supporting androgen production and germ cell differentiation in vitro.


  • Testosterone deficiency in men with end stage renal disease and kidney transplantation: a narrative review

    by Nicholas A. Deebel, Ashley N. Matthew, Justin Loloi, Ari P. Bernstein, Nannan Thirumavalavan, Ranjith Ramasamy

    Testosterone deficiency is a prevalent condition that frequently affects individuals with end-stage renal disease (ESRD) and those who have undergone renal transplantation. While the etiology of this condition is complex, its implications in this population are far-reaching, impacting various domains such as endocrine profile, sexual and erectile function, bone mineral density (BMD), anemia, and graft survival following renal transplantation. Herein, we review the most recent literature exploring the pathophysiology of testosterone deficiency in ESRD and renal transplant patients, examining its diverse effects on this demographic, and assessing the advantages of testosterone replacement therapy (TRT). Existing evidence suggests that TRT is a safe intervention in ESRD and renal transplant patients, demonstrating improvements across multiple domains. Despite valuable insights from numerous studies, a critical need persists for larger, high-quality prospective studies to comprehensively grasp the nuances of TRT, especially in this vulnerable population. Proactive screening and treatment of testosterone deficiency may prove beneficial, emphasizing the urgency for further research in this area.


  • Open Access

    Impact of GLP-1 Agonists on Male Reproductive Health—A Narrative Review

    by Alexandra Aponte Varnum, Edoardo Pozzi, Nicholas Allen Deebel, Aymara Evans, Nathalie Eid, Hossein Sadeghi-Nejad, Ranjith Ramasamy

    Background and objective—Obesity is a prevalent health concern that notably impairs male fertility through hormonal disruptions and other pathophysiological alterations. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can significantly reduce weight. This narrative review synthesizes the existing literature discussing the impact of glucagon-like peptide-GLP-1 RAs on the male reproductive system, particularly on the hypothalamic–pituitary–gonadal axis and spermatogenesis, highlighting their potential impact on male fertility. Material and methods—PubMed database was used for the retrieval of English-language articles published up to November 2023. This non-systematic literature review predominantly concentrates on both pre-clinical and clinical studies pertaining to GLP-1 RAs, specifically exploring their impact on male reproductive hormones and sperm parameters. Results—GLP-1 receptors have been identified within the male reproductive system according to the existing literature. While the exact mechanisms are not well understood, they appear to be involved in glucose homeostasis and energy metabolism, both vital processes in spermatogenesis. Multiple clinical trials have demonstrated the efficacy of GLP-1 RAs for promoting weight loss. Recent studies show that the use of GLP-1 RAs in obese males may enhance sperm metabolism, motility, and insulin secretion in vitro, along with positive effects on the human Sertoli cells. Recent clinical trials discussed in this review demonstrate weight loss associated with GLP-1 RAs is correlated with improvements in sperm count, concentration, and motility. However, the direct impact of GLP-1 RAs on male reproductive hormones remains unclear, necessitating further research to confirm their potential role in treating male infertility. Conclusions—This narrative review summarizes the existing literature discussing the potential impact of GLP-1 RA on the male reproductive system, emphasizing their potential therapeutic role in addressing idiopathic infertility in obese men. Despite numerous studies exploring the influence of GLP-1 and GLP-1 RAs on reproductive hormones, testicular function, and spermatogenesis, further clinical trials are crucial to validate initial evidence. Longer follow-up periods are essential to address uncertainties regarding the long-term repercussions and outcomes of GLP-1 RA use. While this holds true, the current literature suggests that GLP-1RAs show promise as a potential therapeutic approach for improving sperm parameters in obese men.